BioAtla Inc. (BCAB), a clinical-stage biopharmaceutical company, has a couple of near-term catalysts to watch.
The company is developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. It has 4 clinical-stage drug candidates - BA3011, BA3021, BA3071, and BA3182.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com